Caplin Point falls 11% on disappointing Q4 results

The stock fell 11% to Rs 532 on the BSE in intra-day trade after the company's ebitda margin in March quarter declined by 400bps to 35% from 39% in previous year quarter.

Sun Pharma Q4
The revenue from operations declined to ~69.7 bn for the fourth quarter against ~71.3 bn during the same period last year
SI Reporter Mumbai
Last Updated : May 29 2018 | 12:08 PM IST

Don't want to miss the best from Business Standard?

Shares of Caplin Point Laboratories have fallen 11% to Rs 532 per share on the BSE in intra-day trade after the company’s ebitda (earnings before interest, taxation, depreciation and amortization) margin in March quarter (Q4FY18) declined 400bps to 35% from 39% in previous year quarter.

The company’s consolidated net profit during the quarter under review increased by 5.9% at Rs 353 million against Rs 333 million in the corresponding quarter of previous fiscal. Gross revenue grew 19% to Rs 1,463 million over the previous year quarter.

Caplin Point Laboratories' net profit growth was lowest since September 2013 quarter, while revenue growth was lowest since March 2013.

At 11:52 am; the stock was trading 9% lower at Rs 542 on the BSE as compared to 0.10% rise in the S&P BSE Sensex. It was quoting close to its 52-week low of Rs 525 touched on June 2, 2017 on the BSE in intra-day trade. The trading volumes on the counter jumped multiple-fold with a combined 137,853 shares changed hands on the BSE and NSE so far.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Next Story